Biotron Limited (ASX:BIT) Completes Safety Study for HBV Drug
Program Update
Biotron Limited (ASX:BIT) has completed the first stage of its animal study for its lead Hepatitis B Virus (HBV) drug. The safety study established appropriate dosages, with all mice remaining healthy and no organ toxicity observed.
Next Phase
The company will now assess the drug’s antiviral activity in two mouse models to evaluate its effectiveness in early and late HBV infection stages. Funding for this progression was raised through a recent rights issue.
Commercialisation Efforts
Biotron continues its commercialisation activities in collaboration with US-based C14 Consulting Group. At BIO2025 in Boston, the company engaged with potential partners, focusing on its HIV-1 programs.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
